🏛️ Verified NIH Record • Updated 2026-03-24
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (NCT07011706)
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Aclaris Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Who can join: Review the eligibility criteria below.
Location: Aclaris Clinical Site — Phoenix, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- Aclaris Clinical Site — Phoenix, Arizona
- Aclaris Clinical Site — Tucson, Arizona
- Aclaris Study Site — Bryant, Arkansas
- Aclaris Clinical Site — Beverly Hills, California
- Aclaris Study Site — Encinitas, California
- Aclaris Clinical Site — Encino, California
- Aclaris Clinical Site — Huntington Beach, California
- Aclaris Study Site — Los Angeles, California
- Aclaris Study Site — Oceanside, California
- Aclaris Study Site — Santa Monica, California
- Aclaris Clinical Site — Sherman Oaks, California
- Aclaris Clinical Site — Thousand Oaks, California
- Aclaris Study Site — Coral Gables, Florida
- Aclaris Clinical Site — Hollywood, Florida
- Aclaris Clinical Site — Jacksonville, Florida
- Aclaris Clinical Site — Margate, Florida
- Aclaris Study Site — North Miami Beach, Florida
- Aclaris Study Site — Sweetwater, Florida
- Aclaris Study Site — Tampa, Florida
- Aclaris Clinical Site — Wellington, Florida
- Aclaris Clinical Site — Atlanta, Georgia
- Aclaris Clinical Site — Savannah, Georgia
- Aclaris Study Site — Boise, Idaho
- Aclaris Study Site — Clarksville, Indiana
- Aclaris Study Site — Indianapolis, Indiana
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.